Appendix Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the appendix, characterized by the presence of mucinous stroma formation. 
Appendix mucinous adenocarcinomas most frequently harbor alterations in KRAS, GNAS, TP53, SMAD4, and TGFBR2 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, GNAS Mutation, and KRAS G12D are the most common alterations in appendix mucinous adenocarcinoma .
There is 1 clinical trial for appendix mucinous adenocarcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains appendix mucinous adenocarcinoma as an inclusion criterion, 1 is phase 2 (0 open).
Microsatellite is the most frequent gene inclusion criterion for appendix mucinous adenocarcinoma clinical trials .
Ipilimumab and nivolumab are the most common interventions in appendix mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.